| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5079262 | DUSA | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
Sep, 2013
(10 years ago) | |
| US5954703 | DUSA | Method and apparatus for applying 5-aminolevulinic acid |
Oct, 2017
(6 years ago) | |
| US8758418 | DUSA | Illuminator for photodynamic therapy |
May, 2018
(5 years ago) | |
| US8216289 | DUSA | Illuminator for photodynamic therapy |
May, 2018
(5 years ago) | |
| US6709446 | DUSA | Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light |
May, 2018
(5 years ago) | |
| US7723910 | DUSA | Method of photodynamically diagnosing or treating a contoured surface |
Jun, 2019
(4 years ago) | |
| US11077192 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US11690914 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US10357567 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US11135293 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| US11571478 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
Levulan is owned by Dusa.
Levulan contains Aminolevulinic Acid Hydrochloride.
Levulan has a total of 11 drug patents out of which 6 drug patents have expired.
Expired drug patents of Levulan are:
- US5079262
- US5954703
- US8758418
- US8216289
- US6709446
- US7723910
Levulan was authorised for market use on 03 December, 1999.
Levulan is available in solution;topical dosage forms.
Levulan can be used as treatment of actinic keratoses of upper extremities by photodynamic therapy, treatment of non-hyperkeratotic actinic keratoses of face and scalp.
The generics of Levulan are possible to be released after 12 January, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-766) | Mar 09, 2021 |
| M(M-82) | Mar 12, 2013 |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 03 December, 1999
Treatment: Treatment of non-hyperkeratotic actinic keratoses of face and scalp; Treatment of actinic keratoses of upper extremities by photodynamic therapy
Dosage: SOLUTION;TOPICAL
LEVULAN family patents
